Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeri Kim

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset CancerM Eileen Dolan, Omar El Charif, Heather E Wheeler, et al.
BJU International|June 11, 2015
Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillanceJohn W Davis, John F Ward, Curtis A Pettaway, et al.
BJU International|September 24, 2017
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohortPierre Blanchard, John W Davis, Steven J Frank, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2018
Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional StudySarah L Kerns, Chunkit Fung, Patrick O Monahan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2017
Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated OtotoxicityHeather E Wheeler, Eric R Gamazon, Robert D Frisina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2019
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 StudyEmmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, et al.
Science Signaling|May 25, 2017
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancerLikun Li, Styliani Karanika, Guang Yang, et al.
Ebiomedicine|June 21, 2016
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate CancerJeri Kim, John W Davis, Eric A Klein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 TrialEmmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forwardGary J Kelloff, Scott M Lippman, Andrew J Dannenberg, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset CancerM Eileen Dolan, Omar El Charif, Heather E Wheeler, et al.
BJU International|June 11, 2015
Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillanceJohn W Davis, John F Ward, Curtis A Pettaway, et al.
BJU International|September 24, 2017
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohortPierre Blanchard, John W Davis, Steven J Frank, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2018
Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional StudySarah L Kerns, Chunkit Fung, Patrick O Monahan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2017
Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated OtotoxicityHeather E Wheeler, Eric R Gamazon, Robert D Frisina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2019
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 StudyEmmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, et al.
Science Signaling|May 25, 2017
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancerLikun Li, Styliani Karanika, Guang Yang, et al.
Ebiomedicine|June 21, 2016
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate CancerJeri Kim, John W Davis, Eric A Klein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 TrialEmmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forwardGary J Kelloff, Scott M Lippman, Andrew J Dannenberg, et al.
Pageof 11